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Abstract
Background: Cholangiocarcinomas are a heterogeneous group of malignancies arising from a number of cells of
origin along the biliary tree. Although most cases in Western countries are sporadic, large population-based studies
have identified a number of risk factors. This review summarises the evidence behind reported risk factors and
current understanding of the molecular pathogenesis of cholangiocarcinoma, with a focus on inflammation and
cholestasis as the driving forces in cholangiocarcinoma development.
Risk Factors for cholangiocarcinogenesis: Cholestatic liver diseases (e.g. primary sclerosing cholangitis and
fibropolycystic liver diseases), liver cirrhosis, and biliary stone disease all increase the risk of cholangiocarcinoma.
Certain bacterial, viral or parasitic infections such as hepatitis B and C and liver flukes also increase cholangiocarcinoma
risk. Other risk factors include inflammatory disorders (such as inflammatory bowel disease and chronic pancreatitis),
toxins (e.g. alcohol and tobacco), metabolic conditions (diabetes, obesity and non-alcoholic fatty liver disease) and a
number of genetic disorders.
Molecular pathogenesis of cholangiocarcinoma: Regardless of aetiology, most risk factors cause chronic
inflammation or cholestasis. Chronic inflammation leads to increased exposure of cholangiocytes to the
inflammatory mediators interleukin-6, Tumour Necrosis Factor-ɑ, Cyclo-oxygenase-2 and Wnt, resulting in
progressive mutations in tumour suppressor genes, proto-oncogenes and DNA mismatch-repair genes.
Accumulating bile acids from cholestasis lead to reduced pH, increased apoptosis and activation of ERK1/2,
Akt and NF-κB pathways that encourage cell proliferation, migration and survival. Other mediators
upregulated in cholangiocarcinoma include Transforming Growth Factor-β, Vascular Endothelial Growth
Factor, Hepatocyte Growth Factor and several microRNAs. Increased expression of the cell surface receptor
c-Met, the glucose transporter GLUT-1 and the sodium iodide symporter lead to tumour growth,
angiogenesis and cell migration. Stromal changes are also observed, resulting in alterations to the
extracellular matrix composition and recruitment of fibroblasts and macrophages that create a
microenvironment promoting cell survival, invasion and metastasis.
Conclusion: Regardless of aetiology, most risk factors for cholangiocarcinoma cause chronic inflammation
and/or cholestasis, leading to the activation of common intracellular pathways that result in reactive cell
proliferation, genetic/epigenetic mutations and cholangiocarcinogenesis. An understanding of the molecular
pathogenesis of cholangiocarcinoma is vital when developing new diagnostic biomarkers and targeted
therapies for this disease.
Keywords: Cholangiocarcinoma, Aetiology, Pathology, Inflammation, Cholestasis, Molecular pathogenesis,
Biomarkers
* Correspondence: peter.labib.16@ucl.ac.uk
UCL Institute for Liver and Digestive Health, University College London
(Royal Free Hospital Campus), Royal Free Hospital, Pond Street, London NW3
2QG, UK
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Labib et al. BMC Cancer          (2019) 19:185 
https://doi.org/10.1186/s12885-019-5391-0
Background
Cholangiocarcinomas are a heterogeneous group of ma-
lignancies that occur at any location along the biliary
tree [1]. They are anatomically classified as intrahepatic
(arising proximal to the second order bile ducts), perihi-
lar (arising between the second order bile ducts and the
insertion of the cystic duct into the common bile duct)
and distal extrahepatic (arising between the insertion of
the cystic duct and the ampulla of Vater) [2]. Although
this anatomical classification is widely used, other factors
such as tumour growth pattern (mass-forming, periduc-
tal infiltrating or intraductal) and the cell of origin (cho-
langiocytes, peribiliary glands, hepatic progenitor cells or
hepatocytes) provide alternative methods of classification
that may better predict tumour behaviour [1, 3, 4].
Worldwide, the incidence of intrahepatic cholangiocarci-
noma may be increasing whereas perihilar and distal
extrahepatic cholangiocarcinomas are decreasing [5]. In-
cidence rates vary significantly in different countries,
probably due to genetic differences and geographical
variations in risk factors. In Western Europe, incidences
range from 0.45 per 100,000 in Switzerland to 3.36 per
100,000 in Italy [6]. The highest incidence rates are in
Asia due to the prevalence of liver fluke infections (e.g.
85 per 100,000 in Northeast Thailand) [5]. Historical
under-reporting of cholangiocarcinoma [7], geographical
variations in data recording and misclassification of dif-
ferent sub-types means that cancer registry data - and
therefore trends in incidence - should be interpreted
with caution [8].
The well-described hypothesis of the adenoma-dyspla-
sia-carcinoma sequence observed in many other cancers
has not yet been fully characterised in cholangiocarci-
noma, due in part to the varying cells of origin that can
cause the disease. Intraductal papillary neoplasms of the
bile duct demonstrate stepwise progression of oncogenic
molecular pathways and increasing dysplasia highly sug-
gestive of an adenoma to carcinoma sequence [9]. Biliary
intraepithelial neoplasia, a classification that describes
the corresponding molecular and histological changes
seen in flat lesions of the bile duct arising from cholan-
giocytes and peribiliary glands, provides further evidence
for such a sequence [10]. This review summarises the
risk factors and molecular pathogenesis of cholangiocar-
cinoma, with a focus on inflammation and cholestasis as
the driving forces in cholangiocarcinoma development.
Risk factors
Although most cases of cholangiocarcinomas in Western
countries are considered sporadic [11], there are a num-
ber of well-described risk factors (Table 1) [9, 12–24]. It
is proposed that many of these risk factors cause chronic
inflammation and cholestasis, resulting in a cycle of
reactive cell proliferation, genetic and epigenetic muta-
tions and eventual cholangiocarcinogenesis [25].
Cholestatic liver diseases
Primary Sclerosing Cholangitis (PSC) is a chronic chole-
static liver disease of unclear aetiology characterised by
progressive destruction of the intra- and extrahepatic
bile ducts. PSC is strongly associated with inflammatory
bowel disease; 60-80% of patients with PSC have a his-
tory of ulcerative colitis and 7-21% have a history of
Crohn’s disease [26]. Patients with PSC have a 15% life-
time incidence of cholangiocarcinoma (equivalent to a
398-fold increased risk compared to the general popula-
tion) and up to one third will develop cholangiocarcinoma
Table 1 Risk factors for cholangiocarcinoma
Risk factors for cholangiocarcinoma
Cholestatic liver
diseases













Hepatitis B and C
Chronic typhoid disease
Recurrent pyogenic cholangitis
















Non-Alcoholic Fatty Liver Disease (NAFLD)
Genetic disorders Lynch syndrome (Hereditary Non-Polyposis
Colorectal Cancer)
Bile salt transporter protein gene defects
Other Intraductal Papillary Neoplasms of the Bile duct
(IPNB)
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within a year of being diagnosed with PSC [27, 28]. It is
proposed that cholestasis leads to overexposure of cholan-
giocytes to bile acids that cause abnormal cell proliferation
and cholangiocarcinogenesis. Experimental models have
shown that bile acids can phosphorylate Epidermal
Growth Factor Receptor (EGFR) in cholangiocarcinoma
and immortalised cholangiocyte cell lines, leading to cell
growth and proliferation [29]. As PSC causes cholestasis,
the prolonged exposure of cholangiocytes to bile is likely
to be a significant factor in cholangiocarcinogenesis in this
disease.
The Fibropolycystic Liver Diseases (FPLD) are a group
of conditions characterised by cystic lesions in the liver
that are often associated with liver fibrosis and/or renal
abnormalities [30]. They arise as a result of abnormal
development of the embryonic sheet of biliary precursor
cells (the ductal plate) that form the intrahepatic bile
ducts and cholangiocytes [31]. FPLD includes congenital
hepatic fibrosis, Caroli disease, choledochal cysts and
biliary hamartomas [30]. These diseases collectively have
a 15% risk of developing cholangiocarcinoma [32]. How-
ever, the risk of malignant transformation in FPLD varies
depending on the diagnosis; the lifetime risk in patients
with choledochal cysts is 15-20% [33], whereas cholan-
giocarcinogenesis secondary to biliary microhamartomas
is rare and it is still debatable as to whether or not it is a
true risk factor for the disease [34]. The increased risk is
likely to be due to chronic inflammation secondary to
impaired biliary drainage, leading to overexposure of
cholangiocytes to bile acids and deconjugated carcino-
gens that were previously conjugated in the liver, reflux
of pancreatic secretions into the bile duct, and bacterial
contamination [35, 36].
Liver cirrhosis
Liver cirrhosis is characterised by diffuse fibrosis and
nodule formation that occurs as a result of chronic liver
injury [37]. The causes of cirrhosis are numerous and in-
clude alcohol-associated cirrhosis, non-alcoholic steato-
hepatitis (NASH), viral hepatitis and autoimmune
hepatitis as well as a number of metabolic, congenital
and toxic causes [37]. Regardless of aetiology, a number
of population-based studies have found cirrhosis to be
associated with an increased risk of intrahepatic cholan-
giocarcinoma [2]. A meta-analysis in 2012 (seven
case-control studies, n=339,608) found cirrhosis to have
an Odds Ratio (OR) of 22.9 (95% Confidence Interval
(CI) 18-2-28.8) for intrahepatic cholangiocarcinoma
(ICC) [38]. This may be due to the tissue microenviron-
ment seen in cirrhosis (chronic inflammation, increased
cell turnover and progressive fibrosis), which is very
similar to the microenvironments seen in a number of
other high risk conditions such as PSC [39]. Interest-
ingly, a recent retrospective analysis by Petrick et al.
from the US-based Surveillance, Epidemiology, and End
Results (SEER) database (2092 ICC, 2981 extrahepatic
cholangiocarcinomas (ECC), 323,615 controls) found
nonspecific cirrhosis to be associated with both ICC and
ECC (ICC OR 8.26, 95% CI 6.83-9.99; ECC OR 3.83,
95% CI 3.05-4.80) [40]. Whilst the liver microenviron-
ment can explain the increased risk in ICC, it is harder
to conclude that the same mechanism is responsible for
the increased risk of ECC. It may be partly explained by
the observation that cirrhosis is linked to lower levels of
bile acid excretion, which leads to gut microbiome dys-
biosis, a decrease in normal gut microbiata and an in-
crease in pro-inflammatory and pathogenic species
which may in turn lead to bacterial contamination of the
biliary tree [41, 42]. A confounding factor common to
many retrospective analyses is inaccuracy in the anatom-
ical classification of cholangiocarcinoma; many of the
cases of ECC are likely to have been perihilar cholangio-
carcinomas, which due to their proximity to the liver
parenchyma are more likely to be affected by the hepatic
microenvironment.
Biliary stone disease
Gallstones are one of the most common digestive
pathologies in the Western world with a prevalence of
10-20% [43]. Usually composed predominantly of choles-
terol, they can be found within the gallbladder (cholecys-
tolithiasis), the extrahepatic bile duct (choledocholithiasis)
or within the intrahepatic biliary tree (hepatolithiasis).
Gallstones are associated with an increased risk of both
ICC and ECC [40]. In the aforementioned SEER analysis
by Petrick et al., choledocholithiasis was found to confer
an OR of 6.94 (95% CI 5.64-8.54) for ICC and 14.22 (95%
CI 12.48-16.20) for ECC. Cholecystolithiasis conferred a
lower but still significantly increased risk for cholangiocar-
cinoma (OR 3.93 (95% CI 3.49-4.43) and 5.29 (95% CI
4.83-5.80) for ICC and ECC respectively). An interesting
relationship between cholecystectomy and increased risk
of cholangiocarcinoma has been observed, although
whether or not this is causative remains unclear. A recent
systematic review and meta-analysis analysed the data
from 4 cohort studies and 12 case-control studies
(n=220,376 patients with cholecystectomy, 562,392 con-
trols) and found cholecystectomy to be associated with an
increased risk for ECC (OR 2.31, 95% CI 1.34-3.28) but
not ICC (OR 1.40, 95% CI 0.94-1.87) [44]. One causative
mechanism could be the observed change in bile salt com-
position seen after cholecystectomy where there is a re-
duction in the circulating pools of primary bile salts but a
maintained pool of deoxycholic acid, which is associated
with cholangiocyte proliferation (see Cholestasis and bile
acids below) [29, 45]. It is also possible that the increased
risk is secondary to gallstone disease rather than the pro-
cedure itself. This is supported by the observation that the
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increased risk of cholangiocarcinoma reduces to that of
the baseline population within ten years of cholecystec-
tomy [46].
Hepatolithiasis, more commonly found in East Asia
and associated with liver fluke infections [47] and
Caroli disease [48], is also a well-established risk
factor for cholangiocarcinoma [49]. A Nationwide
multi-institutional cross-sectional survey in Japan in
2006 identified 325 patients with hepatolithiasis, 23 of
which having developed cholangiocarcinoma (7%)
[50]. The increased risk is thought to be secondary to
cholestasis from impaired biliary drainage and inflam-
mation secondary to liver flukes and recurrent bacterial
infections [49, 51].
Chronic infections
Liver fluke infections are endemic in China, Thailand,
Korea, Vietnam, Laos, and Cambodia [52]. Cholangio-
carcinoma is associated with infection with Clonorchis
sinensis, Opisthorchis viverrini and Opisthorchis felineus
species, which are usually transmitted through the con-
sumption of raw or undercooked freshwater fish. Mech-
anical damage from the flukes’ oral and ventral hooks,
excreted metabolic products, and granulomatous inflam-
mation surrounding fluke eggs embedded within the
periductal tissue all lead to fibrosis and chronic inflam-
mation that results in DNA damage and carcinogenesis
[52, 53].
Chronic infection with Hepatitis B and C viruses ac-
count for 57% of cases of cirrhosis globally [54]. Several
meta-analyses show an increased risk of ICC in both
hepatitis B and hepatitis C infection [55–57]. The associ-
ation with hepatitis C is stronger in regions where hepa-
titis C is endemic, and likewise for hepatitis B [58]. The
largest meta-analysis (13 case-control studies and three
cohort studies, n=202,135 and n=2,655,902 respectively)
found hepatitis B to have an OR of 3.17 (95% CI
1.99-5.34) and hepatitis C an OR of 3.42 (95% CI
1.96-5.99) [55].
Chronic typhoid carriers carry a six-fold increase for
cholangiocarcinoma [20]. A retrospective analysis of 440
cases of hilar cholangiocarcinoma from a single centre
in Egypt (1995-2004) found 52% of patients had a his-
tory of typhoid infection, although 54% of patients were
also hepatitis C positive, another significant risk factor
that could account for part of the increased risk ob-
served [59].
Recurrent Pyogenic Cholangitis (RPC), more com-
monly encountered in Southeast Asia, is characterised
by recurrent primary bacterial infections of the biliary
tree resulting in the development of pigment stones and
stricturing of the bile ducts [60]. Possible causes are
co-infection with liver flukes or breakdown of conju-
gated bilirubin by bacterial enzymes causing the
formation of pigment stones leading to hepatolithiasis,
although the evidence for these proposed aetiologies re-
mains sparse [60, 61]. One retrospective study from the
US (42 patients, 1986-2005) found 12% of patients de-
veloped cholangiocarcinoma, although it is difficult to
know if these patients had RPC or hepatolithiasis with
recurrent secondary biliary infection. In either case, bil-
iary stone disease associated with recurrent cholangitis
is likely to increase the risk of cholangiocarcinoma.
Human Immunodeficiency Virus (HIV) infection may
increase the risk of ICC [62]. A U.S. case-control study
(625 cases, 90,834 controls) found HIV to have an OR of
5.9 (95% CI 1.8-18.8) [63]. HIV is known to be associ-
ated with an increased risk of cholangitis either directly
(as part of AIDS cholangiopathy) or indirectly via other
opportunistic infections such as cytomegalovirus [63]. It
is important to note that this data came from the pre-
and early combined antiretroviral therapy era, and mul-
tiple relevant confounding diseases with known risk for
cholangiocarcinoma were significantly more prevalent in
the case population (non-specific cirrhosis, alcoholic
liver disease, hepatitis C, diabetes and inflammatory
bowel disease). It is therefore possible that the risk of
cholangiocarcinoma from HIV is overstated.
Regardless of the pathogen, all of the above infections
are characterised by chronicity of infection and sustained
inflammation directly or indirectly affecting the biliary
tree, leading to mutagenesis, cell proliferation and can-
cer development.
Inflammatory disorders
Several inflammatory conditions have been linked to the
development of cholangiocarcinoma. Inflammatory
bowel disease (IBD) – through its association with PSC
– is a risk factor for the development of cholangiocarci-
noma. Cholangiocarcinoma occurs at a younger age in
IBD patients than in the general population (56 years vs
71 years, respectively). In Western countries, cholangio-
carcinoma occurring in patients < 40 years is almost al-
ways associated with IBD [64, 65]. PSC-associated
cholangiocarcinoma in the presence of IBD appears to
follow the dysplasia-carcinoma sequence [66]. The evo-
lution from PSC to cholangiocarcinoma might result
from DNA damage by biliary inflammation and bile
acids in IBD patients with altered DNA repair functions
[67, 68]. Immunosuppression as a result of IBD treat-
ment may also be a contributor in IBD-related carcino-
genesis [69].
Two other conditions that may be associated with
cholangiocarcinoma are chronic pancreatitis and gout
[40]. The mechanisms underlying this may be related to
common pathways of chronic inflammation and/or gut
microbiome dysbiosis [70–72]. Thyrotoxicosis has been
linked to the development of ICC but not ECC (OR
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1.25, 95% CI 1.01-1.54) [40]. Untreated hyperthyroidism
is known to be associated with abnormal liver function;
possible mechanisms include genetic polymorphisms,
oxidative stress, and cholestasis secondary to hepatic
microcirculatory disorders and damage to hepatocyte
and endothelial cell membranes [73–76].
Toxins
There has been conflicting evidence on the risk of alco-
hol and tobacco consumption, largely due to the data
coming from multiple study designs including
population-based, cohort and case-control studies. A re-
cent meta-analysis of 14 cohort studies (n=1,515,741
with 410 cases of ICC) found heavy alcohol consump-
tion (≥5 drinks/day) conferred a hazard ratio of 1.68, al-
though the 95%CI was 0.99-2.86 [77]. In contrast, a
meta-analysis in 2012 of 11 case-control studies (n=3374
ICC, 394,774 controls) found heavy alcohol consump-
tion (>80g/day or alcoholic liver disease) to confer an
OR of 2.81 (95% CI = 1.52-5.21) [38]. This disparity is
likely due to the different design methodologies of the
included studies; alcohol consumption has been shown
to be more strongly associated with liver cancer in
case-control studies [78] and cohort studies tend to ask
participants about recent alcohol consumption, unlike
case-control studies that often estimate lifetime alcohol
consumption [77]. Although a meta-analysis in 2013 (six
case-control studies, one cohort study) found no differ-
ence in cholangiocarcinoma risk between drinkers and
non-drinkers (OR 1.09, 95% CI 0.87-1.37), the recent
SEER analysis by Petrick et al. found patients with
alcohol-related disorders to have an increased risk of
cholangiocarcinoma (OR 2.60, 95% CI 2.23-3.04) [40, 79].
Whilst it is likely that alcohol increases the risk of ICC
through direct chronic hepatic injury and cirrhosis, the
mechanism underlying an increased risk for ECC remains
unclear.
Smoking also increases the risk of both ICC (OR 1.46,
95% CI 1.28-1.66) and ECC (OR 1.77, 95% CI 1.59-1.96)
[40]. It has been proposed that carcinogenic tobacco
compounds damage the biliary epithelium through
direct exposure via the circulation [79].
Thorotrast (thorium oxide) was a radiological contrast
agent used from 1930-1960 [22]. This compound con-
ferred a 300-fold increased risk of developing cholangio-
carcinoma with a latency period of up to 45 years after
exposure [80]. Although the mechanism has not been
fully elucidated, it is known that Thorotrast is taken up
into the reticuloendothelial system and contains an emit-
ter of α-radiation [81]. Combined with its exceptionally
long half-life of 400 years, it is likely that chronic expos-
ure to α-radiation lead to direct DNA damage and
carcinogenesis.
Exposure to chemical toxins has been linked to out-
breaks of cholangiocarcinoma in Italy, West Virginia,
and British Columbia, although convincing evidence is
lacking [82]. Possible culprits include dioxins, vinyl
chloride, nitrosamines, asbestos, the oral contraceptive
pill and isoniazid [36, 83, 84].
Metabolic conditions
Diabetes increases the risk of ICC and ECC [12, 40, 85].
A meta-analysis in 2015 (15 case-control studies and 5
cohort studies, 10,362 patients with cholangiocarcinoma
and 351,908 controls) found a combined OR of 1.74
(95% Confidence Interval (CI): 1.62–1.87), although a
certain degree of heterogeneity was seen in subgroup
analyses of the populations [85]. The recent
meta-analysis by Petrick et al. analysed the risk of Type I
and Type II diabetes separately and found raised ORs
for both ICC and ECC (Type I diabetes OR 1.43 for ICC
and 1.30 for ECC, Type II diabetes OR 1.54 for ICC and
1.45 for ECC [40]. All lower values for 95% CI >1.0)
[40]. Obesity was also shown to be associated with ICC
and ECC, although the OR was greater for ICC (ICC OR
1.42 (95% CI 1.21-1.66), ECC OR 1.17 (95% CI
1.01-1.35)). These findings are consistent with a previous
meta-analysis that found obesity to confer an OR of
1.37 (95 % CI 1.22–1.55) for cholangiocarcinoma,
although no sub-analysis between ICC and ECC was
performed [86].
A new discovery from two recent meta-analyses is the
association between Non-Alcoholic Fatty Liver Disease
(NAFLD) and cholangiocarcinoma [40, 87]. NAFLD is
defined as the presence of hepatic steatosis in the
absence of other causes of hepatic fat accumulation (e.g.
excessive alcohol consumption, hypothyroidism, etc.)
[88]. This can occur in the absence (Non-Alcoholic Fatty
Liver, NAFL) or presence (Non-Alcoholic Steatohepati-
tis, NASH) of inflammation. Non-alcoholic fatty liver
disease confers a roughly 3-fold increase in the risk of
ICC (OR 3.52, 95% CI 2.87-4.32) and ECC (OR 2.93,
95% CI 2.42–3.55) [40].
There are several proposed causative mechanisms for
the inter-related risk factors of diabetes, obesity and
NAFLD. Leptin, the hormone responsible for the sensa-
tion of satiety, is over-excreted when there is excess adi-
pose tissue and has been shown to enhance
cholangiocarcinoma cell growth [89]. Excess adipose tis-
sue causes low-grade systemic inflammation through the
release of inflammatory cytokines such as Interleukin-6
(IL-6) and Tumour Necrosis Factor-ɑ (TNFɑ) resulting
in chronic hepatic inflammation, cirrhosis and fibrosis
[90]. This low grade systemic inflammation is believed
to contribute to the onset of insulin resistance and sub-
sequent development of Type II diabetes [40]. The insu-
lin resistance seen in NAFLD, diabetes and obesity
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results in compensatory systemic hyperinsulinaemia and
increased Insulin-like Growth Factor-1 (IGF-1) produc-
tion in the liver [91, 92]. IGF-1 binding to its receptor
(IGF1-R) leads to upregulation of genes involved in cell
proliferation and survival [93]. A supporting study for
this mechanism by Alvaro et al. found that cholangio-
cytes from biopsies of normal livers (n=10) do not ex-
press significant levels of IGF-1 or IGF1-R on
immunohistochemical staining, but are both intensely
expressed in biopsies of cholangiocarcinoma (n=18) [94].
The association between Type I diabetes and cholangio-
carcinoma may be explained by the high prevalence of
NAFLD (45%) in patients with Type I diabetes [95]. In
conclusion, all three conditions are characterised by
hepatic steatosis, chronic inflammation, insulin
resistance and subsequent upregulation of genes pro-
moting cell turnover, which are all likely to contribute to
cholangiocarcinogenesis.
Genetic diseases
Lynch syndrome (previously known as hereditary
non-polyposis colorectal cancer) is an autosomal domin-
ant disorder caused by a germline mutation of one of
the four DNA mismatch repair genes. This results in an
increased risk of cancers, most commonly colorectal and
endometrial cancers but also cancers of the upper
gastrointestinal tract, urinary tract and brain. Lifetime
risk of a pancreatic or biliary tract cancer is estimated at
2%, although data on cholangiocarcinoma specifically
are lacking [96].
A number of congenital abnormalities confer a higher
risk for developing cholangiocarcinoma. Defects in genes
coding for bile salt transporter proteins (BSEP/ABCB11,
FIC1/ATP8B1 and MDR3/ABCB4) cause cholestasis
leading to the release of inflammatory cytokines,
chronic inflammation and subsequent cholangiocarci-
nogenesis [97].
Intraductal Papillary Neoplasms of the Bile Duct (IPNB)
IPNB (previously known as biliary papillomatosis) is a
rare disease characterised by the presence of multiple
papillary adenomas within the bile ducts. It is associated
with hepatolithiasis and liver fluke infection in Asian
countries (but not in Western countries) implying both
genetic and environmental aetiologies [98]. IPNBs have a
high risk of malignant transformation to cholangiocarci-
noma, estimated to be as high as 40-80%.
Pathogenesis
Although the above risk factors cover a diverse range of
diseases, recurring pathological features in almost all of
them are chronic inflammation and/or cholestasis. These
two features can provide a unified pathway for the mo-
lecular pathogenesis of cholangiocarcinoma by acting on
a series of intracellular pathways that encourage carcino-
genesis (Fig. 1). Whilst this is unlikely to be a complete
model, many of the pathways described below are in-
volved in cholangiocarcinogenesis.
Inflammation
Inflammation is one of the key factors in cholangio-
carcinogenesis. High concentrations of inflammatory
mediators cause progressive mutations in tumour sup-
pressor genes, proto-oncogenes and DNA
mismatch-repair (MMR) genes, resulting in cell prolif-
eration [99].
The inflammatory cytokine Interleukin-6 (IL-6) affects
multiple intracellular pathways that contribute to cho-
langiocarcinogenesis and can be highly overexpressed in
both cultured cholangiocarcinoma cell lines and surgi-
cally resected specimens [100]. In normal cholangio-
cytes, a negative feedback loop for IL-6 exists (IL-6
activates the JAK-STAT pathway, increasing transcrip-
tion of the cytokine suppressor SOCS3 [99]. In cholan-
giocarcinoma, epigenetic silencing of SOCS3 is
observed, reducing the negative feedback [101]. IL-6 also
downregulates specific microRNAs resulting in increased
transcription of DNMT1 (an enzyme used to methylate
cytosine to alter gene expression) resulting in decreased
expression of tumour suppressor genes (see ‘microRNA
changes’ below) [102]. By activating STAT3 (a transcrip-
tion factor in the STAT protein family), IL-6 upregulates
Mcl-1 (an apoptosis inhibitor) preventing cell death
[103]. IL-6 increases expression of progranulin, a precur-
sor protein for granulins (a family of peptides that regu-
late cell growth) resulting in activation of the Akt
pathway which mediates cell survival, mitosis, migration
and angiogenesis [99, 104]. Interestingly, the liver fluke
O. viverrini secretes a granulin homologue (Ov-GRN-1)
that can activate the Akt pathway directly resulting in
cell proliferation and angiogenesis [105–107]. IL-6 also
activates p38 MAPK (a group of protein kinases respon-
sible for cell differentiation and proliferation), resulting
in decreased expression of p21 (a mediator of cellular
senescence) resulting in mitosis [108]. Lastly, IL-6 re-
duces telomere shortening by increasing telomerase ac-
tivity during mitosis, prolonging cell survival [109].
The inflammatory cytokine TNFα causes upregulation
of Activation-Induced cytidine Deaminase (AID), an en-
zyme that creates DNA mutations by converting cyto-
sine to uracil. This results in multiple somatic gene
mutations including in tumour suppressor gene p53 and
the MYC proto-oncogene [110]. One study showed that
AID was barely detectable in biopsies of normal livers
(n=6) but was present in 80% of cases of PSC (n=20)
and 93% of cases of cholangiocarcinoma(n=30) [110].
Cyclo-Oxygenase-2 (COX-2) is an inflammatory medi-
ator that increases prostaglandin production and is
Labib et al. BMC Cancer          (2019) 19:185 Page 6 of 16
known to be raised in tissue samples of PSC and cholan-
giocarcinoma [99, 111]. High COX-2 levels can stimulate
growth in cholangiocarcinoma, and COX-2 inhibitors
can induce apoptosis and inhibit proliferation by de-
creasing Akt pathway stimulation and activating p21 and
other cyclin-dependent kinase inhibitors [112, 113].
COX-2 is partially regulated by inducible nitric oxide
synthase (iNOS) which itself is upregulated by inflam-
matory cytokines. iNOS has been found to be overex-
pressed in biopsy specimens from patients with
advanced (stage III-IV) PSC [114]. The liver fluke O.
viverrini also expresses iNOS, but the relevance of this
has not yet been determined [115]. As well as regulating
COX-2, iNOS also increases nitric oxide (NO) produc-
tion, which results in oxidative DNA damage by affect-
ing DNA repair mechanisms [116]. Both iNOS and NO
upregulate Notch1, a transmembrane receptor with a
wide variety of functions including cell proliferation, dif-
ferentiation and apoptosis. Notch1 interacts with COX-2
to make cells more resistant to apoptosis, and has been
shown to be upregulated in both intrahepatic and extra-
hepatic cholangiocarcinoma [117–119].
Recent insights have highlighted the role of macro-
phages in the activation of the Wnt signalling pathway
in cholangiocarcinogenesis. Inflammatory macrophages
produce Wnt ligands, which normally have the physio-
logical role of mediating epithelial repair when there is
damage to the biliary epithelium [120]. The macro-
phages upregulate the transcription and production of
Wnt7b and Wnt10a, which are excreted and play a para-
crine function by binding to the receptor FZD and its
co-receptors LRP5/LRP6 on cholangiocytes [120]. Acti-
vation of the FZD-LRP5/6 receptor inhibits the intracel-
lular β-catenin degradation complex, leading to an
accumulation of β-catenin [121]. β-catenin interacts with
the TCF/LEF family of transcription factors in the nu-
cleus, leading to increased cell viability and resistance to
apoptosis [122].
Fig. 1 The molecular pathogenesis of cholangiocarcinoma: The majority of risk factors for cholangiocarcinoma cause chronic inflammation and/or
cholestasis. Inflammatory mediators such as IL-6 and TNFɑ activate a number of pathways such as JAK-STAT, p38 MAPK and Akt resulting in
increased cell growth, survival and proliferation. Macrophages secrete ligands that activate the Wnt/β-catenin pathway, leading to TCF/LEF-
mediated gene transcription. Although cholestasis causes inflammation, prolonged exposure of bile acids can have direct cellular effects leading
to upregulation of COX-2 and Mcl-1 resulting in resistance to apoptosis. Liver flukes can also have direct effects on cholangiocytes via activation
of the Akt pathway and upregulation of iNOS, increasing cell survival and proliferation. A number of microRNAs are up- or downregulated in
cholangiocarcinoma. All these alterations lead to well-established oncogenic mechanisms; genetic mutations, increased cell growth, survival, and
apoptotic resistance. For a full description of the depicted pathways, please refer to the article text.
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Cholestasis and bile acids
Under normal physiological circumstances, conjugated
bile acids can act as ligands for the G Protein-Coupled
Bile Acid Receptor 1 (GPBAR1) that affects chloride and
bicarbonate excretion, cell proliferation and apoptosis of
cholangiocytes [123, 124]. Any obstruction of the flow of
bile results in cholestasis and an abnormal accumulation
of bile acids within the biliary tree. This results in a de-
crease in pH leading to enhanced rates of apoptosis
[123]. High expression of GPBAR1 has been detected in
human-derived samples of cholangiocarcinoma and
studies have shown its role as a resistor of apoptosis and
promoter of proliferation in cholangiocytes [124, 125].
Conjugated bile acids can also act as ligands for the
S1PR2 receptor, leading to activation of the ERK1/2, Akt
and Nuclear Factor-Kappa B (NF-κB) pathways resulting
in increased COX-2, cell proliferation, migration and
survival [126–128]. Excess intracellular bile acids also
decrease expression of the nuclear Farnesoid X Receptor
(FXR) [129]. Activation of FXR normally results in the
excretion of bile acids, and a reduction in FXR causes an
intracellular accumulation of bile acids [130]. The bile
acid deoxycholic acid increases the survival of Mcl-1
that promotes proliferation, which may be one mechan-
ism by which increased intracellular bile acids promote
cell survival [29]. Other specific bile acids (e.g. tauro-
cholic acid) are known to stimulate cholangiocyte prolif-
eration [131], and the bile salt glycochenodeoxycholate
has been shown to cause oxidative stress to cholangio-
cytes and cause subsequent genetic alterations [132].
Conjugated bile acids also activate EGFR leading to in-
creased COX-2 expression and activation of the p38
MAPK and p44/42 MAPK pathways [123, 133], and oxy-
sterols (oxidised cholesterol derivatives found in higher
concentrations in cholestatic bile) have also been shown
to increase COX-2 mRNA in cholangiocytes [133].
MicroRNA changes
MicroRNAs (miRNAs) are small non-coding RNA
sequences that regulate post-transcriptional gene expres-
sion. Multiple miRNAs are upregulated or downregu-
lated in cholangiocarcinoma leading to mitosis,
increased cell survival and metastasis [134]. However,
many of the studies investigating miRNA expression in
cholangiocarcinoma compare cholangiocarcinoma cells
with controls, which make it difficult to discern if
changes in miRNA expression are part of the process of
carcinogenesis or the sequelae of established cholangio-
carcinoma [135]. IL-6 has a direct effect on the expres-
sion of some miRNAs, and as chronic inflammation
likely precedes cholangiocarcinoma, these miRNAs are
more likely to be drivers of carcinogenesis. IL-6 in-
creases expression of miR-let-7a, resulting in decreased
expression of the tumour suppressor gene NF2 and
subsequent STAT3 activation [136]. It also downregu-
lates miR-148a and miR-152 resulting in increased
DNMT1 activity leading to methylation of the tumour
suppressor genes p16INK4a and Rassf1a [102]. miR-370 is
also downregulated by IL-6, leading to increased expres-
sion of the oncogene MAP3K8 [137].
The aforementioned upregulation of the Wnt/β-ca-
tenin pathway due to the production of Wnt ligands by
inflammatory macrophages leads to TCF/LEF gene tran-
scription. This is associated with an increased expression
of the long non-coding (lnc) RNA sequence lncRNA
uc.158 [122]. lncRNAs, like miRNAs, regulate
post-transcriptional gene expression and can also inter-
act with miRNAs [135]. lncRNA uc.158 appears to com-
petitively inhibit miR-193b, which normally has a
pro-apoptotic role [122]. This mechanism could explain
one of the ways in which activation of the Wnt/β-ca-
tenin pathway leads to a reduction in apoptosis.
Many other miRNAs are up- or downregulated in in
cholangiocarcinoma, although whether or not many of
them are the cause or symptom of cholangiocarcinogen-
esis remains undetermined. Some example miRNA
changes include:
 Decreased miR-200b, leading to an increase onco-
gene Suz12 and a reduction in E-cadherin expres-
sion resulting in cancer stem cell generation and cell
migration [138, 139];
 Increased miR-141, decreasing expression of
CLOCK, a transcription factor associated with circa-
dian rhythm dysfunction and a number of other ma-
lignancies [137, 140, 141];
 Decreased miR-214, leading to increased expression
of the transcription factor Twist, reducing E-
cadherin levels and subsequent cell migration [142];
and
 Increased miR-21, leading to decreased expression of
the tumour suppressor gene PTEN that results in re-
sistance to apoptotic signals [143].
For a more comprehensive review of micro- and other
non-coding RNA changes associated with cholangiocar-
cinoma, see recent reviews by Wangyang et al. (2018)
[135] and O’Rourke et al. (2018) [134].
Other factors affecting spread and invasion
A complex interplay exists between increased levels of
extracellular ligands, overexpression of membrane-bound
transporters and receptors, and dysregulation of intracel-
lular pathways promoting cell survival and proliferation.
Like miRNA changes, it is difficult to say if some of the
following observations are a cause or symptom of carcino-
genesis due to the design of the experiments that have
identified these changes.
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The increased levels of cytokine Transforming Growth
Factor-β (TGF-β) seen in cholangiocarcinoma causes
E-cadherin (a cell-cell adhesion molecule) to switch to
N-cadherin resulting in loss of adhesion and an ability to
invade [144, 145]. Vascular Endothelial Growth Factor
(VEGF), a signal protein key in angiogenesis, is high in
both cholangiocarcinoma cell lines and tissue samples in
vitro [146]. There is evidence that increased VEGF pro-
duction is driven in part by oestrogens; cholangiocarci-
noma cells express oestrogen receptors, can be
stimulated to proliferate with 17-β oestradiol, and can
have the stimulatory effect of 17-β oestradiol halted with
oestrogen receptor antagonists such as tamoxifen [94,
147, 148]. The cell surface receptor tyrosine kinase
c-Met, usually only present in progenitor and stem cells
for the purpose of organogenesis and wound healing, is
abnormally high in cholangiocarcinoma along with its
only known ligand Hepatocyte Growth Factor (HGF)
leading to tumour growth, angiogenesis and metastasis
[149, 150]. VEGF, c-Met, IL-6 and COX-2 all interact
with the ErbB receptor kinase family leading to activa-
tion of p42/44MAPK (via EGFR and ErB2) and the Akt
pathway (via ErB2-driven PI3K activation) [151]. Bcl-2, a
potent anti-apoptotic protein, has also been found in
high levels in cholangiocarcinoma cell lines [152]. The
Sodium Iodide Symporter (NIS), more commonly known
for its role in iodide uptake in thyroid follicular cells, is
significantly upregulated in cholangiocarcinoma and
there is evidence that this leads to increased cell migra-
tion and invasion [153, 154]. Increased GLUT-1, a glu-
cose transporter commonly found in several cancers due
to increased hypoxia from elevated cell metabolism, is
associated with poorer cell differentiation and increased
migration and metastasis [155].
Significant stromal changes are also seen in cholangio-
carcinoma. Cancer-Associated Fibroblasts (CAFs) in the
surrounding stroma produce various factors that pro-
mote survival, invasion and metastasis via E- to
N-cadherin switching, PI3K-Akt pathway activation and
other currently unknown mechanisms [99]. In vitro and
murine xenograft experiments showed that CAFs ex-
press Platelet Derived Growth Factor Receptor β
(PDGFR-β), and that cultured cholangiocarcinoma cells
secrete the PDGFR-β ligand Platelet Derived Growth
Factor-D (PDGF-D) resulting in fibroblast migration and
recruitment [156]. Selective blocking of PDGF-D (pro-
duced from cholangiocytes) and Rho GTPases (down-
stream effectors of PDGFR-β activation in CAFs)
resulted in reduced CAF migration, supporting this ob-
servation. Higher levels of the matrix metalloproteinases
MMP-7 and MMP-9 have been observed, resulting in in-
creased extracellular matrix breakdown allowing cells to
migrate [157, 158]. Interestingly, the upregulation of
MMP-7 appears to be secondary (at least in part) to
increased expression of the microRNA miR-21 [158].
Macrophages, whilst playing a role in carcinogenesis
through Wnt/β-catenin pathway activation, also appear
to play a key role in tumour progression in established
cholangiocarcinoma. Cancer stem cells located towards
the periphery of the primary tumour appear to secrete a
number of molecules (e.g. Interleukin-13, -34 and oes-
teoactivin) that recruit monocytes and cause them to dif-
ferentiate into Tumour-Associated Macrophages
(TAMs) [159]. A high density of TAMs is associated
with tumour invasion, metastasis and worse patient
outcomes, suggesting that they are used to create a
tumour microenvironment that favours tumour pro-
gression [5, 159].
Genetic and chromosomal factors
Table 2 summarises genetic mutations and polymor-
phisms associated with cholangiocarcinoma [6, 24, 99,
109, 160–171]. Only a few studies have reported on
chromosomal abnormalities in cholangiocarcinoma and
the results have been hard to interpret due to the small
number of samples and wide genetic variation between
the studied population groups. Evidence for gains at 1q,
7p, 8q, 17q, and/or 20q and losses at 1p, 3p, 4q, 6q, 8p,
9pq, 13q, 14q, 17p, 18q and/or 21q have been implicated
[162, 172]. Interestingly, genetic variability in cells other
than cholangiocytes can be associated with cholangiocar-
cinoma. For example, Natural killer cells and
T-lymphocytes express the receptor NKG2D that plays a
role in cell-mediated cytotoxicity and tumour surveil-
lance [161]. One study found that the risk of developing
cholangiocarcinoma in patients with PSC varied signifi-
cantly depending on the NKG2D alleles carried by the
patient; some were protective and others more than
doubled the risk [173].
Discussion
Even when diagnosed at an early stage, cholangiocarci-
noma is an aggressive malignancy with poor patient out-
comes. To reduce global mortality from
cholangiocarcinoma, efforts must be multifaceted and
focus on prevention, early identification of high-risk in-
dividuals and prompt diagnosis as well as
molecular-based targeted therapies for established dis-
ease. Large-scale population studies have provided
insight into a number of preventable and modifiable risk
factors that could significantly influence disease inci-
dence. The early identification of patients with chronic
infections associated with cholangiocarcinoma (e.g. liver
fluke infection and typhoid) can allow for early initiation
of antibacterial/antiparasitic treatment with a high
chance of cure. Although a treatment to eradicate
chronic hepatitis B remains elusive, new treatments for
hepatitis C can cure many patients [174]. Whilst lifelong
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Protein name Normal function(s)a
Congenital mutations/polymorphisms
ABCB4 ATP Binding Cassette
Subfamily B Member 4
MDR3 Multidrug resistance protein 3 Transport of lipids from
hepatocytes to bile
ABCB11 ATP Binding Cassette
Subfamily B Member 11
BSEP Bile Salt Exporter Pump Transport of cholate
conjugates from hepatocytes
to bile
ABCC2 ATP Binding Cassette
Subfamily C Member 2





FIC1 Familial Intrahepatic Cholestasis type 1 Transmembrane phospholipid
transfer
COX-2 Cyclooxygenase 2 COX-2 Cyclooxygenase 2 Inflammatory cytokine
CYP1A2 Cytochrome P450 1A2 CYP1A2 Cytochrome P450 1A2 Xenobiotic metabolism
GST01 Glutathione S-transferase
omega-1
GST01 Glutathione S-transferase omega-1 Detoxification of endogenous
and xenobiotic compounds
KLRK1 Killer Cell Lectin Like
Receptor K1








NAT2 N-Acetyltransferase 2 ARY2 Arylamine N-acetyltransferase 2 Drug and carcinogen
metabolism
NR1H4 Nuclear Receptor Subfamily 1
Group H Member 4
BAR (FXR) Bile acid receptor (Farnesoid X receptor) Negative feedback inhibitor
of bile acid synthesis
TYMS Thymidylate Synthetase TYMS Thymidylate synthase DNA repair
XRCC1 X-Ray Repair Complementing
Defective Repair In Chinese
Hamster Cells 1
XRCC1 DNA repair protein XRCC1 DNA repair
Acquired mutations
APC Adenomatous polyposis coli APC Adenomatous polyposis coli Tumour suppressor
ARID1A AT-Rich Interaction Domain
1A
ARID1a AT-rich interactive domain-containing
protein 1A
Transcription factor
AXIN1 AXIN1 Axin-1 Axis inhibitor protein 1 Regulates apoptosis
BAP1 BRCA1 Associated Protein 1 BAP1 Ubiquitin carboxyl-terminal hydrolase
BAP1
Regulates cell growth
BCL-2 B cell Lymphoma-2 Bcl-2 B-cell lymphoma 2 Regulates apoptosis
BCL2L1 B Cell Lymphoma Like 1 Bcl-xL b B-cell lymphoma-extra large Inhibits apoptosis
Bcl-xS b B-cell lymphoma-extra small Promotes apoptosis
BRAF B Rapidly Accelerated
Fibrosarcoma
B-Raf B-Rapidly Accelerated Fibrosarcoma Proto-oncogene




BRCA2 Breast Cancer 2 BRCA2 Breast cancer type 2 susceptibility protein DNA repair
CCND1 Cyclin D1 CCND1 G1/S-specific cyclin-D1 Regulates cell growth
CDH1 Cadherin 1 E-cadherin Epithelial cadherin Tumour suppressor,
cell adhesion




p16 b Protein 16 Tumour suppressor
p14arf b Protein 14 Alternate Reading Frame Tumour suppressor





EGFR (ErbB-1) Epidermal Growth Factor Receptor Proto-oncogene
ERBB2 Avian Erythroblastosis oncogene B2 ErbB-2 (HER2) Receptor tyrosine-protein kinase Proto-oncogene
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treatment can suppress viral replication and prevent cir-
rhosis, unfortunately access to medication continues to
be limited; less than 2% of people with hepatitis B world-
wide are on treatment [175]. Global public health
initiatives to provide access to medication for hepatitis B
and C, and a focus on the modifiable lifestyle factors of
alcohol, smoking, and obesity, would have a profound ef-
fect on a number of patient outcomes including





Protein name Normal function(s)a
(HER2) erbB-2






FGF19 Fibroblast Growth Factor 19 FGF19 Fibroblast Growth Factor 19 Regulation of bile salt
synthesis
FGFR2 Fibroblast Growth Factor
Receptor 2




















KEAP1 Kelch-like ECH-associated protein 1 Prevents Nrf2-driven
transcription
KRAS Kirsten Rat Sarcoma K-Ras Kirsten Rat Sarcoma Proto-oncogene
LTO1 LTO1, ABCE1 maturation
factor
LTO1 Protein LTO1 homolog Ribosome biogenesis
MCL-1 Myeloid Cell Leukaemia 1 Mcl-1 (3
isoforms) b
Induced myeloid leukaemia cell differentiation
protein Mcl-1
Isoform 1 resists apoptosis,
isoforms 2 & 3 promote
apoptosis




Myc Myc proto-oncogene protein Proto-oncogene
NF1 Neurofibromin 1 NF1 Neurofibromin Stimulates Ras activity






3-kinase catalytic subunit alpha isoform
Generates PIP3 that activates
signalling cascades for cell
growth, survival and motility
PRSS1 Protease, Serine 1 TRY1 Trypsin-1 Serine protease
PRSS2 Protease, Serine 2 TRY2 Trypsin-2 Serine protease






RAD51AP1 RAD51 Associated Protein 1 RAD51AP1 RAD51 Associated Protein 1 DNA damage repair
RASSF1A Ras association domain
family 1 isoform A
RASSF1A Ras association domain-containing
protein 1 isoform A
Tumour suppressor
ROS1 Reactive Oxygen Species








SMAD4 Small Mothers Against
Decapentaplegic 4




SOCS3 Suppressor Of Cytokine
Signaling 3
SOCS3 Suppressor Of Cytokine Signaling 3 Signal transduction inhibitor
TP53 Tumour Protein 53 p53 Protein 53 Tumour suppressor
aRelevant to cholangiocarcinoma development. bThrough alternate splicing
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cholangiocarcinoma incidence. With a global prevalence
of 25%, the recent identification of NAFLD as a greater
risk factor for cholangiocarcinoma than obesity or dia-
betes is significant and likely to pose an increasing
health burden [176]. Screening patients with PSC for
cholangiocarcinoma with regular non-invasive imaging
and the tumour marker Carbohydrate Antigen 19-9 (CA
19-9) is done by many centres, although evidence of effi-
cacy of this approach is lacking [177].
As many of the risk factors above cannot be fully
eradicated, and the majority of cases of cholangiocarci-
noma occur sporadically, an understanding of the mo-
lecular pathogenesis of cholangiocarcinoma can allow
for the identification of potential early diagnostic bio-
markers. For established cholangiocarcinoma, many po-
tential therapeutic targets have been identified in recent
years. Drugs have been developed that can target cell
surface receptors, their ligands or their intracellular
tyrosine kinase components. Example therapies and
their respective targets include [160, 178]:
 Intracellular receptor tyrosine kinase blockade by
lapatinib (ErbB2), erlotinib and vandetanib (EGFR),
sunitinib and cediranib (VEGFR, PDGFR) and
ponatinib (Fibroblast Growth Factor Receptor 2
(FGFR2));
 Extracellular antibody blockade by cetuximab and
panitumumab (EGFR), brontictuzumab (Notch1)
and vanctitumab (FZD7);
 Ligand blockade by bevacizumab (VEGF) and
demcizumab (DLL4, the ligand of Notch1) [179].
As many of these receptors have common downstream
effectors, other therapeutics have been developed to tar-
get their shared intracellular pathways. Both the MAPK/
ERK and Akt pathways are activated by the downstream
sequelae of cholestasis and inflammation (Fig. 1). Sorafe-
nib, as well as acting as a tyrosine kinase inhibitor on a
number of tyrosine kinases including VEGFR-2 and
PDGFR, blocks the MAPK/ERK pathway [180]. mTOR,
a downstream effector of the Akt pathway, can be tar-
geted using the mTOR kinase inhibitor everolimus
[160]. Unfortunately, results from targeted therapies to
date have been disappointing. Targeting of EGFR and its
downstream pathways by cetuximab, panitumumab and
erlotinib has failed to show significant survival benefits
in clinical trials [181–183]. A similar lack of response
has been observed when targeting VEGF and its down-
stream pathways by sorafenib or cediranib [184, 185]. As
a result, current guidelines only support the use of tar-
geted therapies in the context of clinical trials [186].
Promising future targets include Fibroblast Growth Fac-
tor Receptor 2 (FGFR2), Isocitrate Dehydrogenase 1 and 2
(IDH1/2) and Programmed Death Ligand 1 (PD-L1) [8].
Whilst the above results seem discouraging, a significant
confounding factor is that many of the earlier trials did
not perform molecular profiling of enrolled patients to as-
sess whether or not the target was present in all partici-
pants. Future research on targeted therapies will benefit
from the wider use of more appropriate study designs,
such as basket and umbrella trials.
Conclusion
Many risk factors have been implicated in cholangiocar-
cinogenesis, but the evidence supporting each factor is
often limited to population-based studies with the in-
herit limitations of such study designs. Although these
risk factors are variable in cause and nature, the majority
of them have a common theme of causing chronic
inflammation and cholestasis leading to a series of mo-
lecular changes that result in reactive cell proliferation,
genetic/epigenetic mutations and cancer development.
An understanding of the molecular pathogenesis of chol-
angiocarcinoma is vital when developing new diagnostic
biomarkers and targeted therapies to tackle this disease.
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